| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 258 | 2024 | 5189 | 17.760 |
Why?
|
| Diphosphonates | 25 | 2022 | 625 | 4.060 |
Why?
|
| Bone Diseases | 13 | 2021 | 411 | 3.750 |
Why?
|
| Bone Density Conservation Agents | 20 | 2022 | 791 | 3.240 |
Why?
|
| Imidazoles | 15 | 2018 | 1169 | 2.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 64 | 2024 | 11859 | 2.330 |
Why?
|
| Thalidomide | 32 | 2024 | 886 | 2.250 |
Why?
|
| Immunotherapy, Adoptive | 19 | 2024 | 1504 | 2.170 |
Why?
|
| Dexamethasone | 42 | 2024 | 1962 | 2.170 |
Why?
|
| Oligopeptides | 15 | 2024 | 1195 | 2.010 |
Why?
|
| Antineoplastic Agents | 62 | 2024 | 13635 | 1.880 |
Why?
|
| B-Cell Maturation Antigen | 10 | 2023 | 148 | 1.710 |
Why?
|
| Osteoclasts | 18 | 2020 | 713 | 1.630 |
Why?
|
| Cyclin-Dependent Kinases | 5 | 2015 | 659 | 1.470 |
Why?
|
| Osteolysis | 6 | 2017 | 271 | 1.420 |
Why?
|
| Antibodies, Bispecific | 5 | 2024 | 203 | 1.400 |
Why?
|
| Osteoblasts | 11 | 2017 | 1143 | 1.330 |
Why?
|
| Boronic Acids | 32 | 2024 | 915 | 1.300 |
Why?
|
| Bone Neoplasms | 9 | 2022 | 2559 | 1.200 |
Why?
|
| Bone Remodeling | 7 | 2018 | 577 | 1.190 |
Why?
|
| Hydroxamic Acids | 6 | 2017 | 483 | 1.160 |
Why?
|
| Pyrazines | 32 | 2024 | 1204 | 1.150 |
Why?
|
| Apoptosis | 46 | 2024 | 9508 | 1.070 |
Why?
|
| RANK Ligand | 5 | 2018 | 320 | 1.050 |
Why?
|
| Osteonecrosis | 8 | 2014 | 230 | 1.050 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 176 | 0.980 |
Why?
|
| Plasmacytoma | 6 | 2015 | 171 | 0.960 |
Why?
|
| Agammaglobulinemia | 2 | 2023 | 173 | 0.960 |
Why?
|
| Mice, SCID | 26 | 2022 | 2626 | 0.950 |
Why?
|
| Bone Resorption | 8 | 2022 | 717 | 0.930 |
Why?
|
| Antibodies, Monoclonal | 15 | 2023 | 9237 | 0.910 |
Why?
|
| Spinal Cord Compression | 4 | 2023 | 234 | 0.890 |
Why?
|
| Histone Deacetylase Inhibitors | 8 | 2021 | 778 | 0.870 |
Why?
|
| Bone Diseases, Metabolic | 4 | 2017 | 407 | 0.850 |
Why?
|
| B-Cell Activating Factor | 4 | 2016 | 115 | 0.830 |
Why?
|
| Humans | 295 | 2024 | 766117 | 0.800 |
Why?
|
| Neutropenia | 5 | 2023 | 894 | 0.800 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2022 | 31 | 0.790 |
Why?
|
| Cell Line, Tumor | 51 | 2024 | 17071 | 0.790 |
Why?
|
| Bone and Bones | 7 | 2020 | 2555 | 0.780 |
Why?
|
| Pyrimidines | 8 | 2018 | 3050 | 0.780 |
Why?
|
| Drug Resistance, Neoplasm | 24 | 2024 | 5336 | 0.780 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2021 | 33 | 0.770 |
Why?
|
| Bone Marrow | 15 | 2016 | 2916 | 0.730 |
Why?
|
| Fractures, Spontaneous | 3 | 2018 | 230 | 0.730 |
Why?
|
| Bone Marrow Cells | 23 | 2011 | 2411 | 0.730 |
Why?
|
| Lipolysis | 1 | 2022 | 211 | 0.710 |
Why?
|
| Hypercalcemia | 3 | 2022 | 425 | 0.700 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2017 | 1656 | 0.700 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2019 | 1407 | 0.680 |
Why?
|
| Activins | 2 | 2013 | 210 | 0.680 |
Why?
|
| Neoplasm Proteins | 11 | 2016 | 3594 | 0.680 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 633 | 0.670 |
Why?
|
| Urea | 2 | 2013 | 449 | 0.670 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2024 | 2054 | 0.660 |
Why?
|
| Sulfonamides | 4 | 2019 | 1980 | 0.630 |
Why?
|
| Macrocyclic Compounds | 1 | 2019 | 68 | 0.630 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 19 | 2022 | 5752 | 0.620 |
Why?
|
| Immunotherapy | 9 | 2024 | 4746 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 998 | 0.610 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2018 | 79 | 0.610 |
Why?
|
| Drug Synergism | 16 | 2015 | 1754 | 0.600 |
Why?
|
| Tumor Cells, Cultured | 33 | 2022 | 6102 | 0.600 |
Why?
|
| Neoplasm, Residual | 4 | 2023 | 1009 | 0.580 |
Why?
|
| Tumor Microenvironment | 6 | 2019 | 3942 | 0.560 |
Why?
|
| Cancer Vaccines | 4 | 2018 | 1042 | 0.560 |
Why?
|
| Consensus | 7 | 2024 | 3202 | 0.560 |
Why?
|
| Cell Cycle | 11 | 2016 | 2920 | 0.560 |
Why?
|
| Boron Compounds | 5 | 2024 | 195 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2024 | 9378 | 0.520 |
Why?
|
| Melphalan | 12 | 2022 | 425 | 0.500 |
Why?
|
| Glycine | 5 | 2024 | 671 | 0.490 |
Why?
|
| Decorin | 1 | 2015 | 38 | 0.490 |
Why?
|
| Stromal Cells | 19 | 2013 | 1332 | 0.480 |
Why?
|
| Phosphorylcholine | 4 | 2011 | 151 | 0.480 |
Why?
|
| Isoxazoles | 1 | 2016 | 233 | 0.480 |
Why?
|
| Transplantation, Autologous | 15 | 2022 | 2125 | 0.480 |
Why?
|
| Adipocytes | 1 | 2022 | 1196 | 0.480 |
Why?
|
| Pyrazoles | 4 | 2018 | 2031 | 0.470 |
Why?
|
| Benzazepines | 1 | 2016 | 308 | 0.470 |
Why?
|
| Waldenstrom Macroglobulinemia | 7 | 2021 | 1076 | 0.460 |
Why?
|
| Xenograft Model Antitumor Assays | 16 | 2014 | 3604 | 0.450 |
Why?
|
| Fatty Acids | 1 | 2022 | 1805 | 0.450 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 2824 | 0.440 |
Why?
|
| Medical Oncology | 7 | 2022 | 2339 | 0.440 |
Why?
|
| Biological Products | 2 | 2022 | 947 | 0.440 |
Why?
|
| Stem Cell Transplantation | 6 | 2023 | 1600 | 0.430 |
Why?
|
| Lymphoma | 1 | 2022 | 1896 | 0.430 |
Why?
|
| Mesenchymal Stem Cells | 5 | 2017 | 1663 | 0.430 |
Why?
|
| Chemokine CCL3 | 4 | 2011 | 84 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2021 | 5695 | 0.430 |
Why?
|
| Antibodies, Neutralizing | 3 | 2013 | 2011 | 0.420 |
Why?
|
| DNA Damage | 5 | 2016 | 2463 | 0.420 |
Why?
|
| Sirolimus | 3 | 2014 | 1541 | 0.410 |
Why?
|
| Aged | 66 | 2024 | 171219 | 0.410 |
Why?
|
| Mice | 48 | 2022 | 81839 | 0.390 |
Why?
|
| Acrylamides | 1 | 2014 | 260 | 0.390 |
Why?
|
| Male | 88 | 2024 | 363935 | 0.390 |
Why?
|
| Cell Proliferation | 29 | 2018 | 10433 | 0.380 |
Why?
|
| Mutation | 8 | 2024 | 30209 | 0.380 |
Why?
|
| T-Lymphocytes | 13 | 2024 | 10260 | 0.380 |
Why?
|
| Herpesvirus 8, Human | 5 | 2002 | 254 | 0.380 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2024 | 2946 | 0.380 |
Why?
|
| Amyloidosis | 3 | 2012 | 883 | 0.380 |
Why?
|
| Cell Survival | 15 | 2016 | 5747 | 0.370 |
Why?
|
| Down-Regulation | 12 | 2011 | 2927 | 0.370 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2013 | 2046 | 0.370 |
Why?
|
| Spinal Fractures | 4 | 2023 | 702 | 0.370 |
Why?
|
| Morpholines | 1 | 2014 | 584 | 0.370 |
Why?
|
| Caspases | 11 | 2010 | 881 | 0.370 |
Why?
|
| Adjuvants, Immunologic | 3 | 2006 | 993 | 0.350 |
Why?
|
| Hematology | 1 | 2014 | 243 | 0.350 |
Why?
|
| Neoplasms | 12 | 2024 | 22344 | 0.350 |
Why?
|
| Jaw Diseases | 2 | 2008 | 91 | 0.350 |
Why?
|
| Disease-Free Survival | 18 | 2022 | 6840 | 0.350 |
Why?
|
| Female | 86 | 2024 | 396233 | 0.350 |
Why?
|
| Calcification, Physiologic | 1 | 2011 | 167 | 0.350 |
Why?
|
| Middle Aged | 62 | 2024 | 223083 | 0.350 |
Why?
|
| Osteocalcin | 1 | 2011 | 271 | 0.350 |
Why?
|
| Interleukin-6 | 23 | 2015 | 3227 | 0.350 |
Why?
|
| Treatment Outcome | 38 | 2024 | 65219 | 0.340 |
Why?
|
| Salvage Therapy | 7 | 2021 | 1273 | 0.340 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2014 | 2057 | 0.340 |
Why?
|
| Enzyme Activation | 12 | 2016 | 3584 | 0.330 |
Why?
|
| Aged, 80 and over | 28 | 2024 | 59515 | 0.330 |
Why?
|
| Fractures, Compression | 2 | 2023 | 132 | 0.330 |
Why?
|
| Education, Medical, Continuing | 2 | 2014 | 829 | 0.330 |
Why?
|
| Animals | 52 | 2022 | 168800 | 0.320 |
Why?
|
| Flavones | 1 | 2009 | 66 | 0.320 |
Why?
|
| Indoles | 2 | 2015 | 1833 | 0.310 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 713 | 0.310 |
Why?
|
| Piperidines | 3 | 2021 | 1664 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 10 | 2021 | 7424 | 0.300 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2024 | 694 | 0.300 |
Why?
|
| Benzimidazoles | 2 | 2011 | 862 | 0.300 |
Why?
|
| Protease Inhibitors | 8 | 2014 | 750 | 0.300 |
Why?
|
| Glycoproteins | 1 | 2016 | 2196 | 0.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2012 | 1535 | 0.290 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 414 | 0.290 |
Why?
|
| Signal Transduction | 22 | 2018 | 23605 | 0.290 |
Why?
|
| Anemia | 2 | 2023 | 1514 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2014 | 2455 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2021 | 8612 | 0.290 |
Why?
|
| Cyclin D1 | 2 | 2009 | 449 | 0.280 |
Why?
|
| Osteogenesis | 3 | 2011 | 1281 | 0.280 |
Why?
|
| Plasma Cells | 3 | 2019 | 597 | 0.280 |
Why?
|
| Coculture Techniques | 8 | 2022 | 1336 | 0.280 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 7600 | 0.270 |
Why?
|
| Drug Resistance, Multiple | 3 | 2021 | 255 | 0.270 |
Why?
|
| Adult | 49 | 2024 | 223139 | 0.270 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2014 | 2425 | 0.270 |
Why?
|
| Dendritic Cells | 5 | 2013 | 2747 | 0.270 |
Why?
|
| Purines | 2 | 2010 | 616 | 0.260 |
Why?
|
| Disease Management | 5 | 2021 | 2531 | 0.250 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2016 | 4521 | 0.250 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 549 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2020 | 10737 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 6506 | 0.240 |
Why?
|
| Paraproteinemias | 3 | 2019 | 251 | 0.240 |
Why?
|
| Interferon Regulatory Factors | 2 | 2016 | 271 | 0.240 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2021 | 614 | 0.230 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3665 | 0.230 |
Why?
|
| Drug Administration Schedule | 6 | 2021 | 4853 | 0.230 |
Why?
|
| STAT3 Transcription Factor | 4 | 2016 | 872 | 0.220 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 5791 | 0.220 |
Why?
|
| Recurrence | 14 | 2024 | 8494 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 2879 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2014 | 3733 | 0.210 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2023 | 38 | 0.210 |
Why?
|
| Neoplasm Transplantation | 5 | 2016 | 2010 | 0.210 |
Why?
|
| History, 21st Century | 2 | 2020 | 1574 | 0.210 |
Why?
|
| Osteoporosis | 1 | 2012 | 1582 | 0.210 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 1926 | 0.210 |
Why?
|
| Bone Marrow Transplantation | 9 | 2001 | 2729 | 0.210 |
Why?
|
| Cell Adhesion | 12 | 2016 | 3089 | 0.200 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 11200 | 0.200 |
Why?
|
| Osteocytes | 2 | 2017 | 193 | 0.200 |
Why?
|
| Phosphorylation | 14 | 2013 | 8292 | 0.200 |
Why?
|
| Cell Lineage | 2 | 2021 | 2573 | 0.200 |
Why?
|
| Hip Fractures | 1 | 2010 | 995 | 0.190 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2000 | 1559 | 0.190 |
Why?
|
| Clinical Trials as Topic | 9 | 2017 | 8038 | 0.190 |
Why?
|
| Prognosis | 14 | 2024 | 29912 | 0.190 |
Why?
|
| Collagen Type I | 2 | 2015 | 616 | 0.190 |
Why?
|
| Blotting, Western | 9 | 2012 | 5020 | 0.190 |
Why?
|
| Splenomegaly | 1 | 2002 | 191 | 0.190 |
Why?
|
| Immunologic Factors | 8 | 2014 | 1592 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 11 | 2010 | 1935 | 0.180 |
Why?
|
| Combined Modality Therapy | 13 | 2018 | 8525 | 0.180 |
Why?
|
| Kyphoplasty | 2 | 2019 | 45 | 0.180 |
Why?
|
| Transcription Factors | 4 | 2016 | 12130 | 0.170 |
Why?
|
| Antibodies | 2 | 2007 | 2415 | 0.170 |
Why?
|
| Spinal Injuries | 1 | 2023 | 300 | 0.170 |
Why?
|
| Receptors, CCR1 | 2 | 2011 | 30 | 0.170 |
Why?
|
| Doxorubicin | 8 | 2018 | 2226 | 0.160 |
Why?
|
| Osteoprotegerin | 2 | 2018 | 178 | 0.160 |
Why?
|
| Receptors, CXCR4 | 2 | 2021 | 729 | 0.160 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 114 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 12235 | 0.160 |
Why?
|
| Drug Administration Routes | 2 | 2021 | 152 | 0.160 |
Why?
|
| Flow Cytometry | 8 | 2021 | 5881 | 0.160 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 302 | 0.160 |
Why?
|
| Phosphoramide Mustards | 1 | 2018 | 18 | 0.160 |
Why?
|
| Palliative Care | 1 | 2014 | 3639 | 0.160 |
Why?
|
| Nitrogen | 1 | 2020 | 344 | 0.160 |
Why?
|
| Infusions, Intravenous | 3 | 2019 | 2227 | 0.160 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 800 | 0.150 |
Why?
|
| I-kappa B Kinase | 3 | 2009 | 250 | 0.150 |
Why?
|
| Erdheim-Chester Disease | 1 | 2018 | 10 | 0.150 |
Why?
|
| Proteasome Endopeptidase Complex | 5 | 2011 | 1318 | 0.150 |
Why?
|
| Adenine | 2 | 2021 | 994 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2014 | 3787 | 0.150 |
Why?
|
| Remission Induction | 9 | 2023 | 2413 | 0.150 |
Why?
|
| Etodolac | 3 | 2007 | 19 | 0.150 |
Why?
|
| Immunoconjugates | 2 | 2020 | 976 | 0.150 |
Why?
|
| Sodium Fluoride | 1 | 2017 | 60 | 0.140 |
Why?
|
| Cell Line | 7 | 2022 | 15546 | 0.140 |
Why?
|
| Nitroimidazoles | 1 | 2018 | 118 | 0.140 |
Why?
|
| Protein Kinases | 1 | 2004 | 1611 | 0.140 |
Why?
|
| Cell Division | 11 | 2007 | 4466 | 0.140 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 615 | 0.140 |
Why?
|
| Bone Cements | 1 | 2019 | 319 | 0.140 |
Why?
|
| Gene Expression Profiling | 7 | 2016 | 9527 | 0.140 |
Why?
|
| DNA Repair | 1 | 2006 | 2048 | 0.140 |
Why?
|
| Asymptomatic Diseases | 3 | 2017 | 586 | 0.140 |
Why?
|
| Prednisolone | 3 | 2009 | 324 | 0.140 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 708 | 0.140 |
Why?
|
| Up-Regulation | 5 | 2021 | 4133 | 0.130 |
Why?
|
| Administration, Oral | 4 | 2018 | 4016 | 0.130 |
Why?
|
| Enzyme Inhibitors | 8 | 2010 | 3722 | 0.130 |
Why?
|
| Cranial Irradiation | 2 | 1996 | 384 | 0.130 |
Why?
|
| Leukemic Infiltration | 1 | 1996 | 47 | 0.130 |
Why?
|
| Antigens, CD19 | 1 | 2019 | 442 | 0.130 |
Why?
|
| Whole Body Imaging | 1 | 2018 | 281 | 0.130 |
Why?
|
| Medicine, Traditional | 1 | 1996 | 88 | 0.130 |
Why?
|
| NF-kappa B | 6 | 2011 | 2495 | 0.130 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 169 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2018 | 1801 | 0.130 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 1837 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2010 | 1331 | 0.130 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 712 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 1008 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2019 | 637 | 0.120 |
Why?
|
| Histiocytosis | 1 | 2015 | 40 | 0.120 |
Why?
|
| Clodronic Acid | 2 | 2013 | 60 | 0.120 |
Why?
|
| Ikaros Transcription Factor | 1 | 2016 | 230 | 0.120 |
Why?
|
| Survival Analysis | 8 | 2018 | 10087 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 16040 | 0.120 |
Why?
|
| Peptides | 3 | 2018 | 4338 | 0.120 |
Why?
|
| Alendronate | 2 | 2020 | 174 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1602 | 0.120 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2016 | 169 | 0.120 |
Why?
|
| Quality of Life | 5 | 2023 | 13468 | 0.120 |
Why?
|
| Autophagy | 2 | 2015 | 1349 | 0.120 |
Why?
|
| Cell Differentiation | 8 | 2014 | 11642 | 0.120 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2018 | 827 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 3530 | 0.110 |
Why?
|
| Phagosomes | 1 | 2015 | 193 | 0.110 |
Why?
|
| RNA, Transfer | 1 | 2016 | 284 | 0.110 |
Why?
|
| Models, Economic | 1 | 2018 | 716 | 0.110 |
Why?
|
| Immunophenotyping | 5 | 2012 | 1865 | 0.110 |
Why?
|
| Transplantation, Heterologous | 7 | 2010 | 2390 | 0.110 |
Why?
|
| Immunosuppressive Agents | 3 | 2005 | 4213 | 0.110 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 110 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 752 | 0.110 |
Why?
|
| Syndecan-1 | 2 | 2015 | 163 | 0.110 |
Why?
|
| Double-Blind Method | 2 | 2018 | 12426 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 735 | 0.100 |
Why?
|
| beta Catenin | 2 | 2009 | 1047 | 0.100 |
Why?
|
| Anilides | 1 | 2016 | 413 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2012 | 2469 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 506 | 0.100 |
Why?
|
| Ritonavir | 1 | 2014 | 331 | 0.100 |
Why?
|
| Retreatment | 3 | 2020 | 598 | 0.100 |
Why?
|
| Piperazines | 5 | 2011 | 2547 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 943 | 0.100 |
Why?
|
| Cytokines | 6 | 2014 | 7426 | 0.100 |
Why?
|
| Cell Communication | 3 | 2009 | 1660 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1996 | 646 | 0.100 |
Why?
|
| Methotrexate | 2 | 1996 | 1719 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2010 | 439 | 0.100 |
Why?
|
| Vaccination | 2 | 2023 | 3431 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2010 | 715 | 0.100 |
Why?
|
| Retrospective Studies | 10 | 2023 | 81565 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2010 | 329 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2007 | 1241 | 0.090 |
Why?
|
| Positron-Emission Tomography | 4 | 2022 | 6545 | 0.090 |
Why?
|
| Single-Cell Analysis | 3 | 2021 | 2536 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 3801 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 71 | 0.090 |
Why?
|
| Survival Rate | 7 | 2021 | 12827 | 0.090 |
Why?
|
| Drug Therapy, Combination | 4 | 2014 | 6309 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 1740 | 0.090 |
Why?
|
| Retinoblastoma Protein | 2 | 2009 | 666 | 0.090 |
Why?
|
| Acute-Phase Reaction | 1 | 2011 | 91 | 0.090 |
Why?
|
| Follow-Up Studies | 10 | 2023 | 39243 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2018 | 1346 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 895 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 4887 | 0.090 |
Why?
|
| Acid Phosphatase | 2 | 2007 | 137 | 0.090 |
Why?
|
| Rhabdomyosarcoma | 1 | 1993 | 354 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 1227 | 0.090 |
Why?
|
| Disease Progression | 9 | 2022 | 13616 | 0.090 |
Why?
|
| Biphenyl Compounds | 2 | 2006 | 1019 | 0.090 |
Why?
|
| Pyridines | 2 | 2016 | 2889 | 0.090 |
Why?
|
| Cell Movement | 5 | 2016 | 5196 | 0.090 |
Why?
|
| Mutation, Missense | 2 | 2018 | 2590 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2022 | 2029 | 0.090 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 289 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2013 | 454 | 0.090 |
Why?
|
| POEMS Syndrome | 1 | 2010 | 12 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 3 | 2013 | 1490 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2012 | 181 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1029 | 0.090 |
Why?
|
| Cells, Cultured | 9 | 2013 | 18967 | 0.090 |
Why?
|
| Activin Receptors, Type II | 1 | 2010 | 122 | 0.080 |
Why?
|
| Life Style | 1 | 2021 | 3928 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 949 | 0.080 |
Why?
|
| Smad2 Protein | 1 | 2010 | 144 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 1786 | 0.080 |
Why?
|
| Lymphocyte Activation | 5 | 2018 | 5503 | 0.080 |
Why?
|
| Interferon-alpha | 4 | 1998 | 909 | 0.080 |
Why?
|
| Disease Models, Animal | 6 | 2015 | 18321 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2015 | 922 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2009 | 53 | 0.080 |
Why?
|
| Vincristine | 5 | 2001 | 1037 | 0.080 |
Why?
|
| Central Nervous System | 1 | 1996 | 1343 | 0.080 |
Why?
|
| Receptors, CCR5 | 1 | 2011 | 491 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1695 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2016 | 2091 | 0.080 |
Why?
|
| Maytansine | 1 | 2009 | 88 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2008 | 422 | 0.080 |
Why?
|
| Cerulenin | 1 | 2008 | 7 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 1621 | 0.080 |
Why?
|
| Quinazolinones | 1 | 2010 | 219 | 0.080 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2010 | 287 | 0.080 |
Why?
|
| Interferons | 4 | 2001 | 714 | 0.070 |
Why?
|
| Sacrum | 1 | 2010 | 270 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2018 | 1949 | 0.070 |
Why?
|
| Bone Density | 2 | 2012 | 3491 | 0.070 |
Why?
|
| Azepines | 1 | 2010 | 328 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 2795 | 0.070 |
Why?
|
| Myeloid Cells | 1 | 2013 | 839 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2009 | 615 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2271 | 0.070 |
Why?
|
| Cell Fusion | 2 | 2007 | 294 | 0.070 |
Why?
|
| Fever | 2 | 1996 | 1607 | 0.070 |
Why?
|
| Polymethyl Methacrylate | 1 | 2008 | 127 | 0.070 |
Why?
|
| DNA, Neoplasm | 3 | 2007 | 1739 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 361 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2023 | 878 | 0.070 |
Why?
|
| Mandibular Diseases | 1 | 2008 | 117 | 0.070 |
Why?
|
| Albumins | 1 | 2010 | 578 | 0.070 |
Why?
|
| Hydroquinones | 1 | 2007 | 34 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1056 | 0.070 |
Why?
|
| Endothelial Cells | 3 | 2011 | 3586 | 0.070 |
Why?
|
| Caregivers | 2 | 2022 | 2304 | 0.070 |
Why?
|
| Drug Approval | 1 | 2014 | 820 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 4 | 2011 | 2627 | 0.070 |
Why?
|
| Metformin | 1 | 2014 | 903 | 0.070 |
Why?
|
| Risk Factors | 3 | 2023 | 74857 | 0.070 |
Why?
|
| Azo Compounds | 1 | 2007 | 115 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2006 | 3501 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2006 | 1150 | 0.070 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 3436 | 0.070 |
Why?
|
| Ulcer | 1 | 2008 | 202 | 0.070 |
Why?
|
| Authorship | 1 | 2010 | 289 | 0.070 |
Why?
|
| Amyloid | 1 | 2012 | 848 | 0.070 |
Why?
|
| Femoral Fractures | 1 | 2010 | 375 | 0.070 |
Why?
|
| Killer Cells, Natural | 3 | 2010 | 2206 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2007 | 137 | 0.070 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2007 | 185 | 0.070 |
Why?
|
| Actins | 1 | 2014 | 2061 | 0.070 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2006 | 80 | 0.070 |
Why?
|
| Ribonucleotide Reductases | 1 | 2006 | 75 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2007 | 145 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2006 | 169 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2007 | 287 | 0.060 |
Why?
|
| DNA-Binding Proteins | 5 | 2010 | 9601 | 0.060 |
Why?
|
| Isoenzymes | 2 | 2007 | 1688 | 0.060 |
Why?
|
| Adamantane | 1 | 2007 | 148 | 0.060 |
Why?
|
| Naphthalenes | 1 | 2006 | 197 | 0.060 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 130 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 1994 | 1387 | 0.060 |
Why?
|
| Flavoproteins | 1 | 2005 | 40 | 0.060 |
Why?
|
| Cyclophosphamide | 5 | 2001 | 2232 | 0.060 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 657 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 1673 | 0.060 |
Why?
|
| IMP Dehydrogenase | 1 | 2005 | 34 | 0.060 |
Why?
|
| Immunity, Cellular | 3 | 2013 | 1557 | 0.060 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2006 | 101 | 0.060 |
Why?
|
| Azacitidine | 1 | 2007 | 334 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 2898 | 0.060 |
Why?
|
| Cell Growth Processes | 4 | 2007 | 380 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 488 | 0.060 |
Why?
|
| Gingiva | 1 | 2008 | 422 | 0.060 |
Why?
|
| Propylene Glycols | 1 | 2005 | 91 | 0.060 |
Why?
|
| Kidney Diseases | 2 | 2010 | 2100 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2009 | 721 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2018 | 2389 | 0.060 |
Why?
|
| Immunoblotting | 4 | 2014 | 1644 | 0.060 |
Why?
|
| Mucin-1 | 2 | 2000 | 535 | 0.060 |
Why?
|
| Forecasting | 1 | 2014 | 2936 | 0.060 |
Why?
|
| Recombinant Proteins | 6 | 2007 | 6493 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 11035 | 0.060 |
Why?
|
| Bone Regeneration | 1 | 2008 | 436 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 556 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2006 | 412 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5531 | 0.060 |
Why?
|
| Spiro Compounds | 1 | 2005 | 69 | 0.060 |
Why?
|
| Exercise | 1 | 2021 | 5939 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2016 | 1889 | 0.060 |
Why?
|
| Lignans | 1 | 2005 | 83 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2005 | 211 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2020 | 10380 | 0.060 |
Why?
|
| HLA-DR Antigens | 2 | 2013 | 608 | 0.060 |
Why?
|
| Endodeoxyribonucleases | 1 | 2005 | 165 | 0.060 |
Why?
|
| DNA, Viral | 3 | 2000 | 2200 | 0.060 |
Why?
|
| Health Policy | 1 | 1996 | 2700 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 6768 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2007 | 296 | 0.060 |
Why?
|
| Caspase 9 | 3 | 2011 | 184 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2015 | 12775 | 0.060 |
Why?
|
| Disclosure | 1 | 2010 | 756 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 4 | 2007 | 428 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2022 | 54812 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 3796 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2235 | 0.060 |
Why?
|
| Caspase 8 | 3 | 2011 | 198 | 0.050 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2004 | 511 | 0.050 |
Why?
|
| Biomedical Research | 2 | 2010 | 3458 | 0.050 |
Why?
|
| Glucocorticoids | 2 | 2006 | 2156 | 0.050 |
Why?
|
| Glioma | 1 | 2018 | 3491 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 4565 | 0.050 |
Why?
|
| Registries | 1 | 2019 | 8347 | 0.050 |
Why?
|
| Drug Industry | 1 | 2010 | 791 | 0.050 |
Why?
|
| Acyltransferases | 1 | 2005 | 305 | 0.050 |
Why?
|
| Mandible | 1 | 2008 | 746 | 0.050 |
Why?
|
| Radiography | 2 | 2011 | 6943 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2010 | 2877 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 4782 | 0.050 |
Why?
|
| RNA, Small Interfering | 5 | 2011 | 3424 | 0.050 |
Why?
|
| Melanoma | 1 | 2021 | 5695 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2006 | 4342 | 0.050 |
Why?
|
| Hematologic Diseases | 2 | 2021 | 500 | 0.050 |
Why?
|
| Endothelial Growth Factors | 2 | 2003 | 671 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 1068 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3690 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2011 | 678 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2007 | 1996 | 0.050 |
Why?
|
| Lymphokines | 2 | 2003 | 905 | 0.050 |
Why?
|
| Caspase 3 | 3 | 2011 | 731 | 0.050 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2013 | 713 | 0.050 |
Why?
|
| Fatigue | 3 | 2022 | 1552 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8725 | 0.050 |
Why?
|
| Time Factors | 5 | 2018 | 40108 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 12976 | 0.050 |
Why?
|
| Trans-Activators | 3 | 2008 | 2849 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 13085 | 0.050 |
Why?
|
| Antioxidants | 1 | 2009 | 1671 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 975 | 0.040 |
Why?
|
| Immunotherapy, Active | 1 | 2000 | 58 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 2815 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 2430 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2006 | 317 | 0.040 |
Why?
|
| Cytokine Receptor gp130 | 2 | 2016 | 66 | 0.040 |
Why?
|
| Breast Neoplasms | 5 | 2012 | 21074 | 0.040 |
Why?
|
| Leukemia | 1 | 2008 | 1522 | 0.040 |
Why?
|
| Methionine | 1 | 2022 | 569 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 2000 | 182 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2023 | 41684 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 2000 | 78 | 0.040 |
Why?
|
| Idarubicin | 1 | 1999 | 59 | 0.040 |
Why?
|
| United States | 3 | 2018 | 72920 | 0.040 |
Why?
|
| Verapamil | 2 | 1997 | 242 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12803 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 1943 | 0.040 |
Why?
|
| Jaw | 1 | 2019 | 95 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 20700 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2006 | 7850 | 0.040 |
Why?
|
| India | 2 | 1996 | 2334 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1463 | 0.040 |
Why?
|
| Echocardiography | 1 | 2011 | 5041 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3602 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2004 | 1250 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 241 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2007 | 2838 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2000 | 457 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2010 | 1966 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2022 | 2653 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2313 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2000 | 616 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2005 | 1894 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 1657 | 0.040 |
Why?
|
| Vertebroplasty | 1 | 2019 | 78 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2006 | 748 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 859 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 489 | 0.040 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2008 | 102 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 18076 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 9065 | 0.030 |
Why?
|
| I-kappa B Proteins | 2 | 2009 | 210 | 0.030 |
Why?
|
| Myeloma Proteins | 1 | 2017 | 71 | 0.030 |
Why?
|
| Hodgkin Disease | 2 | 2002 | 1383 | 0.030 |
Why?
|
| Decision Trees | 1 | 2019 | 509 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 2627 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5388 | 0.030 |
Why?
|
| Antigens, CD34 | 2 | 1996 | 656 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 1996 | 7474 | 0.030 |
Why?
|
| Spine | 1 | 2023 | 1132 | 0.030 |
Why?
|
| Autoantigens | 1 | 2000 | 886 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12529 | 0.030 |
Why?
|
| Comorbidity | 1 | 2011 | 10579 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2271 | 0.030 |
Why?
|
| Valine | 1 | 2018 | 410 | 0.030 |
Why?
|
| Troponin | 1 | 2019 | 532 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 3546 | 0.030 |
Why?
|
| Paraproteins | 1 | 1995 | 38 | 0.030 |
Why?
|
| Viral Proteins | 2 | 2000 | 1801 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2000 | 852 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 1995 | 155 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2006 | 295 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 2 | 2008 | 322 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 2570 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 1167 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2023 | 2602 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2017 | 382 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 1729 | 0.030 |
Why?
|
| Models, Biological | 1 | 2011 | 9445 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2014 | 241 | 0.030 |
Why?
|
| Methylprednisolone | 3 | 2001 | 386 | 0.030 |
Why?
|
| Neuroectodermal Tumor, Melanotic | 1 | 1994 | 3 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 663 | 0.030 |
Why?
|
| Daunorubicin | 1 | 1994 | 157 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 582 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 15647 | 0.030 |
Why?
|
| Maxillary Neoplasms | 1 | 1994 | 47 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 22341 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2014 | 150 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2017 | 853 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2016 | 415 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 1742 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 36548 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2013 | 44 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 1007 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 1750 | 0.030 |
Why?
|
| HIV Infections | 1 | 2019 | 17535 | 0.030 |
Why?
|
| Asparaginase | 1 | 1994 | 240 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 2702 | 0.030 |
Why?
|
| Heat-Shock Proteins | 2 | 2008 | 790 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2002 | 1404 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 1651 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 568 | 0.030 |
Why?
|
| Cytarabine | 1 | 1994 | 696 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 11094 | 0.020 |
Why?
|
| Gene Expression | 3 | 2014 | 7582 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2000 | 2114 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2000 | 4025 | 0.020 |
Why?
|
| Glutamine | 1 | 2014 | 575 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 426 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2022 | 8724 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 960 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1777 | 0.020 |
Why?
|
| Diketopiperazines | 1 | 2011 | 24 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 594 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2018 | 1377 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 1899 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 26290 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 6059 | 0.020 |
Why?
|
| Mycoses | 1 | 1994 | 389 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 2532 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 387 | 0.020 |
Why?
|
| Cell Separation | 1 | 2016 | 1718 | 0.020 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 2000 | 87 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2018 | 1945 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 1996 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 1814 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2008 | 3405 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1994 | 622 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 422 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 178 | 0.020 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2009 | 32 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 190 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 696 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2018 | 22228 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2016 | 822 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2001 | 330 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2010 | 253 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 2039 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2008 | 65 | 0.020 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2008 | 40 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 1107 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 1872 | 0.020 |
Why?
|
| Precipitating Factors | 1 | 2008 | 51 | 0.020 |
Why?
|
| Brachial Plexus | 1 | 2010 | 171 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4112 | 0.020 |
Why?
|
| Gingival Diseases | 1 | 2008 | 37 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 2 | 2006 | 1370 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 705 | 0.020 |
Why?
|
| Ascites | 1 | 2010 | 336 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 2007 | 186 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2008 | 147 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2001 | 634 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 124 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 4556 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2007 | 121 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 1527 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 2010 | 355 | 0.020 |
Why?
|
| Flavonoids | 2 | 2001 | 446 | 0.020 |
Why?
|
| Mitochondria | 2 | 2014 | 3672 | 0.020 |
Why?
|
| Genes, fos | 1 | 2007 | 176 | 0.020 |
Why?
|
| Cathepsins | 1 | 2008 | 242 | 0.020 |
Why?
|
| Heart Failure | 1 | 2011 | 11837 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2007 | 186 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 2395 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4780 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 642 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3159 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2008 | 225 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 201 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2007 | 175 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1433 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 596 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2006 | 65 | 0.020 |
Why?
|
| Lymphocyte Count | 2 | 2001 | 791 | 0.020 |
Why?
|
| Homeostasis | 1 | 2017 | 3338 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2022 | 4527 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 1491 | 0.020 |
Why?
|
| Benzoquinones | 1 | 2006 | 197 | 0.020 |
Why?
|
| Transfection | 2 | 2007 | 5739 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 1997 | 404 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 582 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2006 | 50 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 4282 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2010 | 904 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2019 | 5595 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 4423 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 210 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2005 | 51 | 0.020 |
Why?
|
| Stem Cells | 2 | 2010 | 3537 | 0.020 |
Why?
|
| Somatomedins | 1 | 2006 | 178 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2009 | 940 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 5300 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2006 | 132 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 2591 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 60 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12061 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 1692 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2213 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2005 | 303 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 2006 | 318 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1376 | 0.010 |
Why?
|
| Paracrine Communication | 1 | 2006 | 277 | 0.010 |
Why?
|
| G2 Phase | 1 | 2005 | 134 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 13483 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2144 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
| Angiopoietin-2 | 1 | 2006 | 186 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2004 | 147 | 0.010 |
Why?
|
| Adolescent | 3 | 2020 | 88819 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2008 | 1881 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 282 | 0.010 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 212 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2005 | 612 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 610 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2006 | 964 | 0.010 |
Why?
|
| Growth Substances | 1 | 2006 | 758 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 2004 | 319 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 858 | 0.010 |
Why?
|
| Incidence | 2 | 2015 | 21513 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 561 | 0.010 |
Why?
|
| Sphingosine | 1 | 2005 | 306 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2009 | 1416 | 0.010 |
Why?
|
| Risk | 1 | 2015 | 9599 | 0.010 |
Why?
|
| Physician's Role | 1 | 2010 | 925 | 0.010 |
Why?
|
| Immune System | 1 | 2008 | 799 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 10860 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2005 | 391 | 0.010 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2008 | 504 | 0.010 |
Why?
|
| Depression | 1 | 2022 | 8230 | 0.010 |
Why?
|
| Cell Death | 1 | 2008 | 1676 | 0.010 |
Why?
|
| Young Adult | 2 | 2020 | 59868 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2005 | 1085 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1996 | 42511 | 0.010 |
Why?
|
| Genotype | 1 | 2016 | 13028 | 0.010 |
Why?
|
| DNA | 2 | 2005 | 7193 | 0.010 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2001 | 46 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 1962 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15882 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1376 | 0.010 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 1 | 2000 | 43 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2013 | 2041 | 0.010 |
Why?
|
| Models, Animal | 1 | 2007 | 2120 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 2897 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 205 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 268 | 0.010 |
Why?
|
| Necrosis | 1 | 2005 | 1614 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2000 | 121 | 0.010 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2000 | 111 | 0.010 |
Why?
|
| STAT2 Transcription Factor | 1 | 2000 | 27 | 0.010 |
Why?
|
| Cell-Free System | 1 | 2000 | 339 | 0.010 |
Why?
|
| Thrombocytopenia | 2 | 1999 | 1172 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2001 | 252 | 0.010 |
Why?
|
| Janus Kinase 1 | 1 | 2000 | 108 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 3051 | 0.010 |
Why?
|
| src Homology Domains | 1 | 2000 | 361 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 890 | 0.010 |
Why?
|
| Pain | 2 | 2010 | 5090 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2000 | 225 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2000 | 261 | 0.010 |
Why?
|
| G1 Phase | 1 | 2000 | 403 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2000 | 738 | 0.010 |
Why?
|
| Cyclin D | 1 | 1999 | 70 | 0.010 |
Why?
|
| Hybridomas | 1 | 2000 | 442 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1999 | 250 | 0.010 |
Why?
|
| RNA Interference | 1 | 2007 | 2828 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 2003 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1999 | 158 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2000 | 340 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2000 | 227 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2000 | 698 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 1724 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 1079 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2000 | 478 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2002 | 995 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2000 | 735 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1999 | 324 | 0.010 |
Why?
|
| Busulfan | 1 | 1998 | 264 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 711 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2003 | 1518 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2000 | 745 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 833 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 24276 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 3818 | 0.010 |
Why?
|
| Filgrastim | 1 | 1996 | 132 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9540 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2210 | 0.010 |
Why?
|
| Child | 2 | 1996 | 80573 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2000 | 562 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2001 | 1205 | 0.010 |
Why?
|
| Cyclins | 1 | 1999 | 598 | 0.010 |
Why?
|
| Convalescence | 1 | 1996 | 107 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 150 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1999 | 992 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 366 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 1524 | 0.010 |
Why?
|
| Cytapheresis | 1 | 1995 | 8 | 0.010 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1996 | 304 | 0.010 |
Why?
|
| Tyrosine | 1 | 2000 | 1427 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 1613 | 0.010 |
Why?
|
| Graft Survival | 2 | 1996 | 3904 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 1995 | 108 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1995 | 361 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 1916 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1996 | 234 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1995 | 205 | 0.010 |
Why?
|
| Epitopes | 1 | 2000 | 2523 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1998 | 630 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2002 | 2868 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1743 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 1996 | 301 | 0.010 |
Why?
|
| Phenotype | 2 | 2003 | 16716 | 0.010 |
Why?
|
| DNA Replication | 1 | 2000 | 1428 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 4909 | 0.010 |
Why?
|
| Temperature | 1 | 2000 | 2227 | 0.010 |
Why?
|
| Kinetics | 1 | 2000 | 6273 | 0.010 |
Why?
|
| Plasma | 1 | 1995 | 583 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 14066 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1995 | 1605 | 0.010 |
Why?
|
| Drug Utilization | 1 | 1996 | 1187 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1996 | 955 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1995 | 685 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 5995 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 3692 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1996 | 2060 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1997 | 2596 | 0.000 |
Why?
|
| Protein Binding | 1 | 1999 | 9301 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1995 | 2394 | 0.000 |
Why?
|
| Genetic Variation | 1 | 2000 | 6612 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1997 | 3617 | 0.000 |
Why?
|
| Length of Stay | 1 | 1996 | 6490 | 0.000 |
Why?
|
| Age Factors | 1 | 1997 | 18386 | 0.000 |
Why?
|
| Infant | 1 | 1994 | 36427 | 0.000 |
Why?
|